Additional file 2: Figure S1. of Development of an integrated approach for comparison of in vitro and in vivo responses to particulate matter

Resazurin reduction by J774A.1 (A) and A549 (B) cells exposed to particles. Average fold-effect (FE) over control ± standard error values are shown (n = 5). ATP content of J774A.1 (C) and A549 (D) cells exposed to particles. (n = 3). Proliferation in J774A.1 (E) and A549 (F) cells exposed to particles. (n = 3). Two way ANOVA; Resazurin assay, J774A.1, PM main effect, p < 0.001, SRM-1648 vs. DWR1, EHC-98 or EHC-2000 (†), SRM-1649 vs. DWR1, EHC-93, EHC-98, EHC-2000, TiO2 or CRI (‡), Tukey test, p < 0.05, Dose main effect, p < 0.001, Doses 0, 10 or 20 vs. 40, 80 or 160 (#), Dose 40 vs. 80 or 160 (not shown), Dose 80 vs. 160 (not shown), Tukey test, p < 0.05; Resazurin assay, A549, PM × Dose interaction, p = 0.001, asterisks (*) represent effects significantly different from control, Tukey test, p < 0.05. ATP assay, J774A.1, PM main effect, p < 0.001, EHC-98 vs. SRM-1648, SRM-1649 or EHC-2000 (†), SRM-1649 vs. DWR1, TiO2 or EHC-93 (‡), Tukey test, p < 0.05, Dose main effect, p < 0.001, Dose 160 vs. all doses (#), Tukey test, p < 0.001; ATP assay, A549, PM main effect, p < 0.001, DWR1 vs. all particles (†), EHC-93 vs. SRM-1649, CRI or TiO2 (‡), Tukey test, p < 0.05, Dose main effect, p < 0.001, Dose 10 vs. 0, 40, 80 or 160 (not shown), Dose 20 vs. 80 (not shown), Dose 160 vs. 0, 20, 40 or 80 (#), Tukey test, p < 0.05. BrdU assay, J774A.1, PM main effect, p < 0.001, DWR1 or CRI vs. EHC-93, EHC-98, EHC-2000, SRM-1648, SRM-1649 or TiO2 (†), Tukey test, p < 0.05, Dose main effect, p < 0.001, Doses 0 or 10 vs. 20, 40, 80 or 160 (‡), Doses 20 or 40 vs. 80 or 160 (not shown), Dose 80 vs. 160 (not shown), Tukey test, p < 0.05; BrdU assay, A549, Dose main effect, p < 0.001, Dose 10 vs. 0, 20, 80 or 160 (†), Dose 40 vs. 80 or 160 (‡), Tukey test, p < 0.05. (DOCX 80 kb)